Press Releases

Date Title and Summary Additional Formats
Toggle Summary Cellectar Biosciences Announces Presentations at 2014 American Society of Clinical Oncology (ASCO) Annual Meeting
MADISON, Wis., May 30, 2014 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (OTCQX:CLRB), announced that presentations highlighting the company's cancer and cancer stem cell-targeting delivery and retention platform of optimized phospholipid ether analogs (PLEs) and its radiotherapeutic agent,
View HTML
Toggle Summary Cellectar Biosciences Appoints Chad J. Kolean Chief Financial Officer
MADISON, Wis., May 29, 2014 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (OTCQX:CLRB), a clinical stage biopharmaceutical company developing innovative agents for the detection and treatment of cancer, today announced the appointment of Chad J. Kolean as chief financial officer, effective May
View HTML
Toggle Summary Cellectar Biosciences Reports First Quarter 2014 Financial Results and Recent Highlights
Management to Host Conference Call and Webcast at 5:00 PM EDT
View HTML
Toggle Summary Cellectar Biosciences to Host Conference Call on May 14th to Discuss First Quarter 2014 Results and Provide Quarterly Update on Development Progress
MADISON, Wis., May 12, 2014 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (OTCQX:CLRB), a biopharmaceutical company developing innovative agents for the detection and treatment of cancer, announced that management will host a conference call and live webcast to discuss first quarter 2014
View HTML
Toggle Summary Cellectar Biosciences Announces Receipt of Orphan Designation of I-124-CLR1404 as Diagnostic for the Management of Glioma from U.S. Food and Drug Administration
Company Expects to Complete Ongoing Multi-Center Phase II Imaging Trial of I-124-CLR1404 in Patients with Glioblastoma By Year-End
View HTML
Toggle Summary Dr. Simon Pedder Becomes President and Chief Executive Officer of Cellectar Biosciences
MADISON, Wis., April 2, 2014 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (OTCQX:CLRB), a clinical stage biopharmaceutical company developing innovative agents for the detection and treatment of cancer, announced that effective April 1, 2014, Dr. Simon Pedder transitioned to President and CEO of
View HTML
Toggle Summary Cellectar Biosciences to Host Conference Call on March 25th to Discuss Full Year 2013 Financial Results and Provide Quarterly Update on Development Progress
      MADISON, Mar 19, 2014 (GLOBE NEWSWIRE via COMTEX) -- Cellectar Biosciences, Inc. (otcqx:CLRB), a biopharmaceutical company developing innovative agents for the detection and treatment of cancer, announced that management will host a conference call and live webcast to discuss full year 2013
View HTML
Toggle Summary Cellectar Announces Initiation of Phase II Imaging Trial With I-124-CLR1404 in Patients With Newly Diagnosed or Recurrent Glioblastoma
  Cellectar Expects Results from this 36-Patient, Multi-Center Imaging Trial by Year-End 2014 MADISON, Wis., March 04, 2014, – Cellectar Biosciences, Inc. (OTCQX: CLRB) a biopharmaceutical company developing innovative agents for the detection and treatment of cancer, announced enrollment of the
View HTML
Toggle Summary Novelos Therapeutics Announces Corporate Name Change to Cellectar Biosciences, Inc.
  Stock to be Quoted Under Ticker Symbol CLRB Beginning February 12, 2014 MADISON, Wis., February 11, 2014,  – Novelos Therapeutics, Inc. (OTCQX: NVLT) a biopharmaceutical company developing novel agents for the detection and treatment of cancer, announced that, effective today, its corporate name
View HTML
Toggle Summary Novelos Therapeutics to Present at the 16th Annual BIO CEO & Investor Conference
  MADISON, Wis. (February 10, 2014) – Novelos Therapeutics, Inc. (OTCQX: NVLT) a biopharmaceutical company developing novel agents to detect, treat and monitor a broad spectrum of cancers, today announced that Dr. Simon Pedder, acting president and CEO of Novelos, will present at the 16th Annual
View HTML